# To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B

> **NCT05760781** · PHASE2 · TERMINATED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 9 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** STSG-0002 Injection

## Key facts

- **NCT ID:** NCT05760781
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-25
- **Primary completion:** 2023-12-11
- **Final completion:** 2023-12-11
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited.
- **Last updated:** 2023-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760781, "To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05760781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*